Disponible en / Available in:
Español
The fight against multi-resistant bacteria is on the right track following the creation of the company Evolving Therapeutics, thanks to the financial support of the Respiralia Foundation, the support of the University of Valencia and the work of researchers Pilar Domingo-Calap and Marisa Domingo-Calap and their team.
8 months of intense growth
On 28 April 2023, the company Evolving Therapeutics was created with the aim of moving from basic research to effective treatment of multidrug-resistant bacteria through phage therapy. The Respiralia Foundation provided €180,000.00 to get the company off the ground, thanks to a generous donation received from Dogstars Operations.
The strategy is to attack this type of bacteria with a One Health solution, which includes animal, plant and human health, and therefore requires significant infrastructure and manpower.
In these 8 months of 2023, activities have been carried out to train staff, set up and fine-tune laboratories, as well as start customer services.
Public recognition for great work
Evolving Therapeutics, thanks to a serious and professional work, has been recognised with the following awards in its first months of existence:
- VLC-STARTUP 2023 Award
- UV del 5UCV Startup Award
- Entrepreneurship Award of the Universitat de València – Santander Universities
- Start up of Major Impact Award 2023 of the VII National Congress of Entrepreneurial Scientists
- Bioval Best Partner Award 2023
- Paterna Ciudad de Empresas 2023 Award in the Best Start-up category
- Best Triple Impact Start-Up Award 2023
A curriculum within the reach of few companies of which the Respiralia Foundation is particularly proud.
Ongoing treatments
To date, 5 phage therapy treatments have been started on 4 people and 1 treatment against Xilella fastidiosa requested by the Balearic Government’s Department of the Environment. These treatments have been carried out in close collaboration with the I2SysBio Universitat de València-CSIC research group.
New challenges for 2024
The creation of a biosafety room exclusively for this type of research is the priority for 2024, in addition to the continued acquisition of equipment to enable the development of the projects.
The Respiralia Foundation will continue to support this project because of its potential to counteract bacterial resistance to antibiotics, a major problem in Cystic Fibrosis and many other respiratory and non-respiratory diseases.
#TogetheragainstCF
